Low Cost and Effective Drug to Treat Central Retinal Vein Occlusion (CRVO)
Retinal vein occlusion (RVO) is the second most common eye disease after diabetic retinopathy. Around 16 million people are affected with the disease every year in the world. Bevacizumab (Avastin) drug found to be as effective as Aflibercept (Eylea) drug for treating central retinal vein occlusion in the eye, finds a new study funded by the National Eye Institute (NEI).
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer